Overview

Reversal of Remimazolam by a Single Dose of Flumazenil

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Remimazolam, a brand-new sedative which has benzodiazepine property. It is an ultra-short acting sedative and regarded as a proper drug for procedural sedation.
Phase:
N/A
Details
Lead Sponsor:
Konkuk University Medical Center
Treatments:
Flumazenil